Clinical trial results:
A Phase 1b/2, Randomized, Controlled, Open-Label Study Evaluating the Safety and Efficacy of ABBV-927 Administered in Combination with Modified FOLFIRINOX (mFFX) With or Without Budigalimab compared to mFFX in Subjects with Untreated Metastatic Pancreatic Adenocarcinoma

Summary

EudraCT number	2020-005767-31
Trial protocol	ES
Global end of trial date	25 March 2024

Results information

Result version number	v1 (current)
This version publication date	20 March 2025
First version publication date	20 March 2025

Trial information

Trial identification

Sponsor protocol code	M20-732

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT04807972
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	AbbVie Deutschland GmbH & Co. KG
Sponsor organisation address	AbbVie House, Vanwall Business Park, Vanwall Road, Maidenhead, Berkshire, United Kingdom, SL6 4UB
Public contact	AbbVie, Global Medical Services, 001 8006339110, abbvieclinicaltrials@abbvie.com
Scientific contact	AbbVie, Global Medical Services, 001 8006339110, abbvieclinicaltrials@abbvie.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	25 March 2024
Is this the analysis of the primary completion data?	Yes
Primary completion date	25 March 2024
Global end of trial reached?	Yes
Global end of trial date	25 March 2024
Was the trial ended prematurely?	Yes

Notes:

General information about the trial

Main objective of the trial:

Phase 1b: The primary objective for the Phase 1b part of the study is to assess the safety and tolerability of mFFX combined with ABBV-927 and budigalimab in subjects with previously untreated metastatic pancreatic adenocarcinoma.
Phase 2: The primary objective for the Phase 2 part of the study is to assess the effect on overall survival of mFFX combined with ABBV-927 with or without budigalimab compared to mFFX alone in subjects with treatment-naïve metastatic pancreatic adenocarcinoma.

Protection of trial subjects:

Prior to any study-related screening procedures being performed on the subject or any medications being discontinued by the subject in order to participate in this study, the informed consent statement will be reviewed, signed, and dated by the subject or their legally authorized representative, the person who administered the informed consent, and any other signatories according to local requirements. A copy of the signed informed consent will be given to the subject and the original will be placed in the subject's medical record.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	28 May 2021
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Australia: 3
Country: Number of subjects enrolled	Israel: 4
Country: Number of subjects enrolled	Puerto Rico: 1
Country: Number of subjects enrolled	Spain: 7
Country: Number of subjects enrolled	United States: 13
Worldwide total number of subjects	28
EEA total number of subjects	7

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0

Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	17
From 65 to 84 years	11
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

A total of 28 subjects were enrolled in the dose escalation phase (Phase 1b) of the study (N=9 in Cohort 1 and N=19 in Cohort 2). The sponsor closed the study for business not safety reasons. At the time of notification to close, active subjects remained in Cohort 2 of the Phase 1b dose escalation, and enrollment in Phase 2 was not initiated.

Period 1

Period 1 title	Phase 1b Overall Period (overall period)
Is this the baseline period?	Yes
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	mFFX + ABBV-927 0.1 mg/kg + budigalimab 500 mg

Arm description:

Dose escalation stage: ABBV-927 was administered via IV infusion Q4W at dose of 0.1 mg/kg. Budigalimab (ABBV-181) was administered as an IV infusion Q4W at a dose of 500 mg.

Arm type	Experimental
Investigational medicinal product name	ABBV-927
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder and solvent for solution for infusion
Routes of administration	Intravenous drip use

Dosage and administration details:

ABBV-927 was administered via IV infusion Q4W at dose of 0.1 mg/kg.

Each treatment cycle was 28 days. ABBV-927 and budigalimab were administered on Day 3 of each cycle. For the mFFX components, oxaliplatin, leucovorin, and irinotecan were administered on Days 1 and 15 of each cycle and 5-fluorouracil was administered on Days 1, 3 and 15, 17 of each cycle. Subjects were treated until radiographic disease progression per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, unacceptable toxicity, or other withdrawal/discontinuation criteria were fulfilled.

Investigational medicinal product name	Budigalimab
Investigational medicinal product code	
Other name	ABBV-181
Pharmaceutical forms	Powder and solvent for solution for infusion
Routes of administration	Intravenous drip use

Dosage and administration details:

Budigalimab (ABBV-181) was administered as an IV infusion Q4W at a dose of 500 mg.

Each treatment cycle was 28 days. ABBV-927 and budigalimab were administered on Day 3 of each cycle. For the mFFX components, oxaliplatin, leucovorin, and irinotecan were administered on Days 1 and 15 of each cycle and 5-fluorouracil was administered on Days 1, 3 and 15, 17 of each cycle. Subjects were treated until radiographic disease progression per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, unacceptable toxicity, or other withdrawal/discontinuation criteria were fulfilled.

Investigational medicinal product name	modified FOLFIRINOX
Investigational medicinal product code	
Other name	mFFX
Pharmaceutical forms	Powder and solvent for solution for infusion
Routes of administration	Intravenous drip use

Dosage and administration details:

Each treatment cycle was 28 days. ABBV-927 and budigalimab were administered on Day 3 of each cycle. For the mFFX components, oxaliplatin, leucovorin, and irinotecan were administered on Days 1 and 15 of each cycle and 5-fluorouracil was administered on Days 1, 3 and 15, 17 of each cycle. Subjects were treated until radiographic disease progression per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, unacceptable toxicity, or other withdrawal/discontinuation criteria were fulfilled.

Arm title	mFFX + ABBV-927 0.3 mg/kg + budigalimab 500 mg

Arm description:

Dose escalation stage: ABBV-927 was administered via IV infusion Q4W at dose of 0.3 mg/kg. Budigalimab (ABBV-181) was administered as an IV infusion Q4W at a dose of 500 mg.

Arm type	Experimental
Investigational medicinal product name	ABBV-927
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder and solvent for solution for infusion
Routes of administration	Intravenous drip use

Dosage and administration details:

ABBV-927 was administered via IV infusion Q4W at dose of 0.3 mg/kg.

Each treatment cycle was 28 days. ABBV-927 and budigalimab were administered on Day 3 of each cycle. For the mFFX components, oxaliplatin, leucovorin, and irinotecan were administered on Days 1 and 15 of each cycle and 5-fluorouracil was administered on Days 1, 3 and 15, 17 of each cycle. Subjects were treated until radiographic disease progression per (Response Evaluation Criteria in Solid Tumors) RECIST v1.1, unacceptable toxicity, or other withdrawal/discontinuation criteria were fulfilled.

Investigational medicinal product name	Budigalimab
Investigational medicinal product code	
Other name	ABBV-181
Pharmaceutical forms	Powder and solvent for solution for infusion
Routes of administration	Intravenous drip use

Dosage and administration details:

Budigalimab (ABBV-181) was administered as an IV infusion Q4W at a dose of 500 mg.

Each treatment cycle was 28 days. ABBV-927 and budigalimab were administered on Day 3 of each cycle. For the mFFX components, oxaliplatin, leucovorin, and irinotecan were administered on Days 1 and 15 of each cycle and 5-fluorouracil was administered on Days 1, 3 and 15, 17 of each cycle. Subjects were treated until radiographic disease progression per (Response Evaluation Criteria in Solid Tumors) RECIST v1.1, unacceptable toxicity, or other withdrawal/discontinuation criteria were fulfilled.

Investigational medicinal product name	modified FOLFIRINOX
Investigational medicinal product code	
Other name	mFFX
Pharmaceutical forms	Powder and solvent for solution for infusion
Routes of administration	Intravenous drip use

Dosage and administration details:

Each treatment cycle was 28 days. ABBV-927 and budigalimab were administered on Day 3 of each cycle. For the mFFX components, oxaliplatin, leucovorin, and irinotecan were administered on Days 1 and 15 of each cycle and 5-fluorouracil was administered on Days 1, 3 and 15, 17 of each cycle. Subjects were treated until radiographic disease progression per (Response Evaluation Criteria in Solid Tumors) RECIST v1.1, unacceptable toxicity, or other withdrawal/discontinuation criteria were fulfilled.

Number of subjects in period 1	mFFX + ABBV-927 0.1 mg/kg + budigalimab 500 mg	mFFX + ABBV-927 0.3 mg/kg + budigalimab 500 mg
Started	9	19
Completed	0	0
Not completed	9	19
Adverse event, non-fatal	-	1
Other	1	1
No longer clinically benefiting	1	-
Progressive disease	7	12
Withdrawal by subject	-	5

Baseline characteristics

Reporting groups	
Reporting group title	mFFX + ABBV-927 0.1 mg/kg + budigalimab 500 mg
Reporting group description:	
Dose escalation stage: ABBV-927 was administered via IV infusion Q4W at dose of 0.1 mg/kg. Budigalimab (ABBV-181) was administered as an IV infusion Q4W at a dose of 500 mg.	
Reporting group title	mFFX + ABBV-927 0.3 mg/kg + budigalimab 500 mg
Reporting group description:	
Dose escalation stage: ABBV-927 was administered via IV infusion Q4W at dose of 0.3 mg/kg. Budigalimab (ABBV-181) was administered as an IV infusion Q4W at a dose of 500 mg.	

Reporting group values	mFFX + ABBV-927 0.1 mg/kg + budigalimab 500 mg	mFFX + ABBV-927 0.3 mg/kg + budigalimab 500 mg	Total
Number of subjects	9	19	28
Age categorical Units: Subjects			
< 40 years	0	1	1
40 - 64 years	4	12	16
≥ 65 years	5	6	11
Age continuous Units: years			
arithmetic mean	64.7	60.1	
standard deviation	± 4.53	± 10.27	-
Gender categorical Units: Subjects			
Female	4	9	13
Male	5	10	15

End points

End points reporting groups

Reporting group title	mFFX + ABBV-927 0.1 mg/kg + budigalimab 500 mg

Reporting group description:

Dose escalation stage: ABBV-927 was administered via IV infusion Q4W at dose of 0.1 mg/kg. Budigalimab (ABBV-181) was administered as an IV infusion Q4W at a dose of 500 mg.

Reporting group title	mFFX + ABBV-927 0.3 mg/kg + budigalimab 500 mg

Reporting group description:

Dose escalation stage: ABBV-927 was administered via IV infusion Q4W at dose of 0.3 mg/kg. Budigalimab (ABBV-181) was administered as an IV infusion Q4W at a dose of 500 mg.

Primary: Phase 1b: Percentage of participants experiencing Adverse Events

End point title	Phase 1b: Percentage of participants experiencing Adverse Events[1]

End point description:

An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related.

End point type	Primary

End point timeframe:

Up to 6 months

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: There will be no statistical testing for all of the efficacy and safety endpoints.

End point values	mFFX + ABBV-927 0.1 mg/kg + budigalimab 500 mg	mFFX + ABBV-927 0.3 mg/kg + budigalimab 500 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	9	19		
Units: percentage of participants				
number (not applicable)	100	100		

Statistical analyses

No statistical analyses for this end point

Primary: Phase 1b: Number of Participants with Potentially Clinically Significant (PCS) Laboratory (Hematological and Chemistry) Values

End point title	Phase 1b: Number of Participants with Potentially Clinically Significant (PCS) Laboratory (Hematological and Chemistry) Values[2]

End point description:

Baseline values and changes from baseline will be summarized for each scheduled post-baseline visit for laboratory data as applicable. If more than one measurement exists for a participant on a particular day and time, an arithmetic average will be calculated. This average will be that participant's measurement

for that day. For participants that do not have any post-baseline measurements, only their baseline values will be summarized.

End point type	Primary

End point timeframe:

Up to 6 months

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: There will be no statistical testing for all of the efficacy and safety endpoints.

End point values	mFFX + ABBV-927 0.1 mg/kg + budigalimab 500 mg	mFFX + ABBV-927 0.3 mg/kg + budigalimab 500 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0[3]	0[4]		
Units: participants				

Notes:

[3] - Laboratory values over time were not summarized due to this study being terminated early.

[4] - Laboratory values over time were not summarized due to this study being terminated early.

Statistical analyses

No statistical analyses for this end point

Primary: Phase 1b: Number of Participants with Potentially Clinically Significant (PCS) Vital Signs

End point title	Phase 1b: Number of Participants with Potentially Clinically Significant (PCS) Vital Signs[5]

End point description:

Baseline values and changes from baseline will be summarized for each scheduled post-baseline visit for vital signs data.

End point type	Primary

End point timeframe:

Up to 6 months

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: There will be no statistical testing for all of the efficacy and safety endpoints.

End point values	mFFX + ABBV-927 0.1 mg/kg + budigalimab 500 mg	mFFX + ABBV-927 0.3 mg/kg + budigalimab 500 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	9[6]	18[7]		
Units: participants				
Diastolic Blood Pressure < 50 & ≥ 20 mmHg Decrease	0	0		
Diastolic Blood Pressure > 100 & > 0 mmHg Increase	0	0		
Pulse Rate < 50 & ≥ 30 beats/min Decrease	0	1		
Pulse Rate > 120 & ≥ 30 beats/min Increase	0	1		
Systolic Blood Pressure < 70 & ≥ 30 mmHg Decrease	0	0		

Systolic Blood Pressure > 160 & > 0 mmHg Increase	1	2		
Temperature ≤ 35.6 ◦C	4	7		
Temperature ≥ 38.8 ◦C	0	1		

Notes:

[6] - Denominator indicates the number of subjects with non-missing baseline and post baseline values.

[7] - Denominator indicates the number of subjects with non-missing baseline and post baseline values.

Statistical analyses

No statistical analyses for this end point

Primary: Phase 1b: Number of Participants with Dose Limiting Toxicities (DLT)

End point title	Phase 1b: Number of Participants with Dose Limiting Toxicities (DLT)[8]

End point description:

A DLT is defined as any serious AE for which a clear alternative cause cannot be established (e.g., attributed to the disease under study, another disease, or to a concomitant medication [e.g., COVID-19 vaccine] by the investigator or AbbVie Therapeutic Area (TA) MD] that occurs during the DLT observation period, and is not listed as a predefined exception in the protocol.

End point type	Primary

End point timeframe:

Up to 6 months

Notes:

[8] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: There will be no statistical testing for all of the efficacy and safety endpoints.

End point values	mFFX + ABBV-927 0.1 mg/kg + budigalimab 500 mg	mFFX + ABBV-927 0.3 mg/kg + budigalimab 500 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	9	19		
Units: participants	1	1		

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 1b: Time to Maximum Observed Plasma Concentration (Tmax)

End point title	Phase 1b: Time to Maximum Observed Plasma Concentration (Tmax)

End point description:

The time to maximum plasma concentration (Tmax; measured in hours) is the time it takes for a drug to achieve Cmax.

End point type	Secondary

End point timeframe:

Up to approximately 3 months

End point values	mFFX + ABBV-927 0.1 mg/kg + budigalimab 500 mg	mFFX + ABBV-927 0.3 mg/kg + budigalimab 500 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	7	15		
Units: hours				
median (full range (min-max))	1.75 (1.75 to 3.5)	1.75 (1.75 to 5.5)		

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 1b: Quality of Life(QoL)-Measure Participant Overall Perceptions of Their Change in Pancreatic Cancer Symptoms includes the Patient Global Impression of Severity (PGIS) and the Patient Global Impression of Change (PGIC)

End point title	Phase 1b: Quality of Life(QoL)-Measure Participant Overall Perceptions of Their Change in Pancreatic Cancer Symptoms includes the Patient Global Impression of Severity (PGIS) and the Patient Global Impression of Change (PGIC)

End point description:

Patient Global Impression of Severity (PGIS) and Patient Global Impression of Change (PGIC) will measure participants' overall perceptions of their pancreatic cancer symptoms over time.

End point type	Secondary

End point timeframe:

Up to approximately 25 months

End point values	mFFX + ABBV-927 0.1 mg/kg + budigalimab 500 mg	mFFX + ABBV-927 0.3 mg/kg + budigalimab 500 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0[9]	0[10]		
Units: participants				

Notes:

[9] - Data were not collected for this Outcome Measure due to early termination of the study.

[10] - Data were not collected for this Outcome Measure due to early termination of the study.

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 1b: Clinical Benefit Rate (CBR)

End point title	Phase 1b: Clinical Benefit Rate (CBR)

End point description:

Clinical Benefit Rate (CBR) is defined as the percentage of participants whose best overall response is either Complete Response (CR), Partial Response (PR), or stable disease (SD) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

For stable disease to be considered clinical benefit it must last for at least 28 weeks.

End point type	Secondary

End point timeframe:

Up to approximately 27 months

End point values	mFFX + ABBV-927 0.1 mg/kg + budigalimab 500 mg	mFFX + ABBV-927 0.3 mg/kg + budigalimab 500 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	9[11]	19[12]		
Units: percentage of participants				
number (confidence interval 95%)	22.2 (2.8 to 60.0)	31.6 (12.6 to 56.6)		

Notes:

[11] - 95% confidence interval is from the exact binomial distribution

[12] - 95% confidence interval is from the exact binomial distribution

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 1b: Duration of Response (DOR) for Participants Who Achieve a Documented Confirmed Response of CR/PR

End point title	Phase 1b: Duration of Response (DOR) for Participants Who Achieve a Documented Confirmed Response of CR/PR

End point description:

DOR is defined as the time from the initial response of CR/PR per investigator review according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria to the first occurrence of radiographic disease progression, clinical progression or death from any cause whichever occurs first.

"99999" indicates non-estimable.

End point type	Secondary

End point timeframe:

Up to approximately 27 months

End point values	mFFX + ABBV-927 0.1 mg/kg + budigalimab 500 mg	mFFX + ABBV-927 0.3 mg/kg + budigalimab 500 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	9	19		
Units: months				
median (confidence interval 95%)	15.2 (12.39 to 99999)	7.5 (4.17 to 99999)		

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 1b: Progression Free Survival (PFS)

End point title	Phase 1b: Progression Free Survival (PFS)

End point description:

PFS is defined as the time from randomization to a documented radiographic disease progression according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, clinical progression or death from any cause, whichever occurs earlier.

End point type	Secondary

End point timeframe:

Up to approximately 24 months after study drug discontinuation

End point values	mFFX + ABBV-927 0.1 mg/kg + budigalimab 500 mg	mFFX + ABBV-927 0.3 mg/kg + budigalimab 500 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	9	19		
Units: months				
median (confidence interval 95%)	5.8 (1.81 to 13.96)	7.4 (3.12 to 9.43)		

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 1b: Maximum Plasma Concentration (Cmax)

End point title	Phase 1b: Maximum Plasma Concentration (Cmax)

End point description:

The maximum plasma concentration (Cmax; measured in ng/mL) is the highest concentration that a drug achieves in the blood after administration in a dosing interval.

End point type	Secondary

End point timeframe:

Up to approximately 3 months

End point values	mFFX + ABBV-927 0.1 mg/kg + budigalimab 500 mg	mFFX + ABBV-927 0.3 mg/kg + budigalimab 500 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	7	15		
Units: µg/mL				
geometric mean (geometric coefficient of variation)	0.692 (± 51)	5.36 (± 58)		

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 1b: Area Under the Concentration-time Curve Over the Time Interval (AUC) in Plasma

End point title	Phase 1b: Area Under the Concentration-time Curve Over the Time Interval (AUC) in Plasma

End point description:

The area under the plasma concentration-time curve (AUC; measured in ng*hr/mL) is a method of measurement of the total exposure of a drug in blood plasma.

End point type	Secondary

End point timeframe:

Up to approximately 3 months.

End point values	mFFX + ABBV-927 0.1 mg/kg + budigalimab 500 mg	mFFX + ABBV-927 0.3 mg/kg + budigalimab 500 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	7[13]	15[14]		
Units: µg*h/mL				
geometric mean (geometric coefficient of variation)	84.2 (± 43)	421 (± 34)		

Notes:

[13] - AUC336 is reported; N=4

[14] - AUC336 is reported; N=7

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 1b: Objective Response Rate (ORR)

End point title	Phase 1b: Objective Response Rate (ORR)

End point description:

ORR is defined as the percentage of participants whose best overall response is either complete response (CR) or partial response (PR) per investigator assessment according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

End point type	Secondary

End point timeframe:

Up to approximately 27 months

End point values	mFFX + ABBV-927 0.1 mg/kg + budigalimab 500 mg	mFFX + ABBV-927 0.3 mg/kg + budigalimab 500 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	9[15]	19[16]		
Units: percentage of participants				
number (confidence interval 95%)	22.2 (2.8 to 60.0)	21.1 (6.1 to 45.6)		

Notes:

[15] - 95% confidence interval is from the exact binomial distribution

[16] - 95% confidence interval is from the exact binomial distribution

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

All-cause mortality were reported from enrollment to study termination, median time on follow-up was 24.7 months for Cohort 1 (mFFX + ABBV-927 0.1 mg/kg + budigalimab 500 mg) and 16.6 months for Cohort 2 (mFFX + ABBV-927 0.3 mg/kg + budigalimab 500 mg).

Assessment type	Systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	26.1

Reporting groups

Reporting group title	mFFX_ABBV-927_0.1_mg_kg_budigalimab-Dose_Escalation
Reporting group description: -	
Reporting group title	mFFX_ABBV-927_0.3_mg_kg_budigalimab-Dose_Escalation
Reporting group description: -	

Serious adverse events	mFFX_ABBV-927_0.1_mg_kg_budigalimab-	mFFX_ABBV-927_0.3_mg_kg_budigalimab-	
Total subjects affected by serious adverse events			
subjects affected / exposed	8 / 9 (88.89%)	12 / 19 (63.16%)	
number of deaths (all causes)	7	13	
number of deaths resulting from adverse events	1	4	
Investigations			
BLOOD CREATININE INCREASED			
subjects affected / exposed	1 / 9 (11.11%)	0 / 19 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
HYPOTENSION			
subjects affected / exposed	1 / 9 (11.11%)	0 / 19 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
DEEP VEIN THROMBOSIS			
subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			

ANAEMIA			
subjects affected / exposed	1 / 9 (11.11%)	1 / 19 (5.26%)	
occurrences causally related to treatment / all	2 / 2	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
FEBRILE NEUTROPENIA			
subjects affected / exposed	1 / 9 (11.11%)	0 / 19 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
NEUTROPENIA			
subjects affected / exposed	1 / 9 (11.11%)	0 / 19 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
MALAISE			
subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
FATIGUE			
subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
DISEASE PROGRESSION			
subjects affected / exposed	1 / 9 (11.11%)	2 / 19 (10.53%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 2	
PYREXIA			
subjects affected / exposed	1 / 9 (11.11%)	2 / 19 (10.53%)	
occurrences causally related to treatment / all	1 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
SUDDEN DEATH			
subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	

Immune system disorders			
CYTOKINE RELEASE SYNDROME			
subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
GASTROINTESTINAL HAEMORRHAGE			
subjects affected / exposed	1 / 9 (11.11%)	0 / 19 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
ENTERITIS			
subjects affected / exposed	1 / 9 (11.11%)	0 / 19 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
DYSPHAGIA			
subjects affected / exposed	1 / 9 (11.11%)	0 / 19 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
ABDOMINAL PAIN			
subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
VOMITING			
subjects affected / exposed	0 / 9 (0.00%)	3 / 19 (15.79%)	
occurrences causally related to treatment / all	0 / 0	2 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
PANCREATITIS ACUTE			
subjects affected / exposed	1 / 9 (11.11%)	0 / 19 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
NAUSEA			
subjects affected / exposed	0 / 9 (0.00%)	3 / 19 (15.79%)	
occurrences causally related to treatment / all	0 / 0	2 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	

INTESTINAL OBSTRUCTION			
subjects affected / exposed	1 / 9 (11.11%)	0 / 19 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
IMMUNE-MEDIATED HEPATITIS			
subjects affected / exposed	1 / 9 (11.11%)	0 / 19 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
HYPERBILIRUBINAEMIA			
subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
PLEURAL EFFUSION			
subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
HYPOXIA			
subjects affected / exposed	1 / 9 (11.11%)	0 / 19 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
ACUTE KIDNEY INJURY			
subjects affected / exposed	1 / 9 (11.11%)	0 / 19 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
BACK PAIN			
subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
BACTERAEMIA			

subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
STAPHYLOCOCCAL BACTERAEMIA			
subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
SEPSIS			
subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
NEUTROPENIC SEPSIS			
subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	1 / 1	
HEPATOBILIARY INFECTION			
subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
ESCHERICHIA INFECTION			
subjects affected / exposed	1 / 9 (11.11%)	0 / 19 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
EPIGLOTTITIS			
subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
ENTEROCOCCAL INFECTION			
subjects affected / exposed	1 / 9 (11.11%)	0 / 19 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
DIVERTICULITIS INTESTINAL PERFORATED			

subjects affected / exposed	1 / 9 (11.11%)	0 / 19 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
CATHETER SITE INFECTION			
subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
CLOSTRIDIUM DIFFICILE COLITIS			
subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
COVID-19 PNEUMONIA			
subjects affected / exposed	1 / 9 (11.11%)	0 / 19 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
DEHYDRATION			
subjects affected / exposed	1 / 9 (11.11%)	1 / 19 (5.26%)	
occurrences causally related to treatment / all	1 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
DECREASED APPETITE			
subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	mFFX_ABBV-927_0.1_mg_kg_budigalimab-	mFFX_ABBV-927_0.3_mg_kg_budigalimab-	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	9 / 9 (100.00%)	19 / 19 (100.00%)	
Vascular disorders			
HYPOTENSION			

subjects affected / exposed	0 / 9 (0.00%)	2 / 19 (10.53%)	
occurrences (all)	0	3	
HYPERTENSION			
subjects affected / exposed	1 / 9 (11.11%)	1 / 19 (5.26%)	
occurrences (all)	1	1	
FLUSHING			
subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)	
occurrences (all)	0	1	
DEEP VEIN THROMBOSIS			
subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)	
occurrences (all)	0	1	
General disorders and administration site conditions			
ASTHENIA			
subjects affected / exposed	5 / 9 (55.56%)	5 / 19 (26.32%)	
occurrences (all)	11	9	
CATHETER SITE SWELLING			
subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)	
occurrences (all)	0	1	
FATIGUE			
subjects affected / exposed	3 / 9 (33.33%)	9 / 19 (47.37%)	
occurrences (all)	8	15	
FEELING HOT			
subjects affected / exposed	1 / 9 (11.11%)	0 / 19 (0.00%)	
occurrences (all)	1	0	
HYPOTHERMIA			
subjects affected / exposed	1 / 9 (11.11%)	0 / 19 (0.00%)	
occurrences (all)	1	0	
INFLUENZA LIKE ILLNESS			
subjects affected / exposed	1 / 9 (11.11%)	0 / 19 (0.00%)	
occurrences (all)	1	0	
MALAISE			
subjects affected / exposed	0 / 9 (0.00%)	2 / 19 (10.53%)	
occurrences (all)	0	2	
MUCOSAL INFLAMMATION			

subjects affected / exposed	4 / 9 (44.44%)	2 / 19 (10.53%)	
occurrences (all)	6	4	
OEDEMA PERIPHERAL			
subjects affected / exposed	4 / 9 (44.44%)	3 / 19 (15.79%)	
occurrences (all)	4	4	
PAIN			
subjects affected / exposed	1 / 9 (11.11%)	0 / 19 (0.00%)	
occurrences (all)	1	0	
PYREXIA			
subjects affected / exposed	3 / 9 (33.33%)	6 / 19 (31.58%)	
occurrences (all)	4	8	
TEMPERATURE INTOLERANCE			
subjects affected / exposed	1 / 9 (11.11%)	1 / 19 (5.26%)	
occurrences (all)	1	3	
Reproductive system and breast disorders			
PELVIC PAIN			
subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)	
occurrences (all)	0	1	
Respiratory, thoracic and mediastinal disorders			
RHINORRHOEA			
subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)	
occurrences (all)	0	1	
PULMONARY EMBOLISM			
subjects affected / exposed	0 / 9 (0.00%)	3 / 19 (15.79%)	
occurrences (all)	0	3	
PNEUMOTHORAX			
subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)	
occurrences (all)	0	1	
PNEUMONITIS			
subjects affected / exposed	1 / 9 (11.11%)	0 / 19 (0.00%)	
occurrences (all)	1	0	
PLEURAL EFFUSION			
subjects affected / exposed	0 / 9 (0.00%)	2 / 19 (10.53%)	
occurrences (all)	0	2	
NASAL PRURITUS			

subjects affected / exposed	1 / 9 (11.11%)	0 / 19 (0.00%)	
occurrences (all)	1	0	
NASAL CONGESTION			
subjects affected / exposed	1 / 9 (11.11%)	0 / 19 (0.00%)	
occurrences (all)	1	0	
INTRANASAL HYPOAESTHESIA			
subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)	
occurrences (all)	0	2	
COUGH			
subjects affected / exposed	2 / 9 (22.22%)	0 / 19 (0.00%)	
occurrences (all)	5	0	
DYSPHONIA			
subjects affected / exposed	1 / 9 (11.11%)	1 / 19 (5.26%)	
occurrences (all)	1	1	
DYSPNOEA EXERTIONAL			
subjects affected / exposed	1 / 9 (11.11%)	0 / 19 (0.00%)	
occurrences (all)	1	0	
EPISTAXIS			
subjects affected / exposed	0 / 9 (0.00%)	3 / 19 (15.79%)	
occurrences (all)	0	5	
HICCUPS			
subjects affected / exposed	0 / 9 (0.00%)	2 / 19 (10.53%)	
occurrences (all)	0	3	
Psychiatric disorders			
INSOMNIA			
subjects affected / exposed	0 / 9 (0.00%)	3 / 19 (15.79%)	
occurrences (all)	0	4	
DEPRESSION			
subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)	
occurrences (all)	0	1	
ANXIETY			
subjects affected / exposed	1 / 9 (11.11%)	0 / 19 (0.00%)	
occurrences (all)	1	0	
Investigations			
BLOOD CREATININE INCREASED			

subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)	
occurrences (all)	0	1	
ALANINE AMINOTRANSFERASE INCREASED			
subjects affected / exposed	1 / 9 (11.11%)	2 / 19 (10.53%)	
occurrences (all)	1	2	
AMYLASE INCREASED			
subjects affected / exposed	1 / 9 (11.11%)	0 / 19 (0.00%)	
occurrences (all)	1	0	
ASPARTATE AMINOTRANSFERASE INCREASED			
subjects affected / exposed	1 / 9 (11.11%)	1 / 19 (5.26%)	
occurrences (all)	1	1	
BLOOD ALKALINE PHOSPHATASE INCREASED			
subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)	
occurrences (all)	0	1	
BLOOD BICARBONATE DECREASED			
subjects affected / exposed	1 / 9 (11.11%)	0 / 19 (0.00%)	
occurrences (all)	1	0	
BLOOD BILIRUBIN INCREASED			
subjects affected / exposed	1 / 9 (11.11%)	1 / 19 (5.26%)	
occurrences (all)	1	1	
BLOOD LACTATE DEHYDROGENASE INCREASED			
subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)	
occurrences (all)	0	2	
BLOOD TRIGLYCERIDES INCREASED			
subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)	
occurrences (all)	0	1	
GAMMA-GLUTAMYLTRANSFERASE DECREASED			
subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)	
occurrences (all)	0	1	
GAMMA-GLUTAMYLTRANSFERASE INCREASED			
subjects affected / exposed	0 / 9 (0.00%)	3 / 19 (15.79%)	
occurrences (all)	0	8	
HEART RATE IRREGULAR			

subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)	
occurrences (all)	0	3	
LIPASE INCREASED			
subjects affected / exposed	1 / 9 (11.11%)	0 / 19 (0.00%)	
occurrences (all)	1	0	
LYMPHOCYTE COUNT DECREASED			
subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)	
occurrences (all)	0	1	
NEUTROPHIL COUNT DECREASED			
subjects affected / exposed	1 / 9 (11.11%)	3 / 19 (15.79%)	
occurrences (all)	2	7	
PANCREATIC ENZYMES INCREASED			
subjects affected / exposed	1 / 9 (11.11%)	0 / 19 (0.00%)	
occurrences (all)	1	0	
PLATELET COUNT DECREASED			
subjects affected / exposed	1 / 9 (11.11%)	2 / 19 (10.53%)	
occurrences (all)	1	3	
RETICULOCYTE COUNT INCREASED			
subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)	
occurrences (all)	0	1	
URINARY CASTS PRESENT			
subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)	
occurrences (all)	0	1	
WEIGHT DECREASED			
subjects affected / exposed	2 / 9 (22.22%)	8 / 19 (42.11%)	
occurrences (all)	3	12	
WHITE BLOOD CELL COUNT DECREASED			
subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)	
occurrences (all)	0	1	
WHITE BLOOD CELL COUNT INCREASED			
subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)	
occurrences (all)	0	1	
Injury, poisoning and procedural complications			

FALL			
subjects affected / exposed	0 / 9 (0.00%)	2 / 19 (10.53%)	
occurrences (all)	0	3	
INFUSION RELATED REACTION			
subjects affected / exposed	0 / 9 (0.00%)	4 / 19 (21.05%)	
occurrences (all)	0	4	
ROAD TRAFFIC ACCIDENT			
subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)	
occurrences (all)	0	1	
SEROMA			
subjects affected / exposed	1 / 9 (11.11%)	0 / 19 (0.00%)	
occurrences (all)	1	0	
WOUND DEHISCENCE			
subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)	
occurrences (all)	0	1	
Cardiac disorders			
PALPITATIONS			
subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)	
occurrences (all)	0	1	
VENTRICULAR TACHYCARDIA			
subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)	
occurrences (all)	0	1	
Nervous system disorders			
PERIPHERAL SENSORY NEUROPATHY			
subjects affected / exposed	0 / 9 (0.00%)	4 / 19 (21.05%)	
occurrences (all)	0	7	
BALANCE DISORDER			
subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)	
occurrences (all)	0	1	
CHOLINERGIC SYNDROME			
subjects affected / exposed	1 / 9 (11.11%)	0 / 19 (0.00%)	
occurrences (all)	2	0	
COLD DYSAESTHESIA			
subjects affected / exposed	1 / 9 (11.11%)	3 / 19 (15.79%)	
occurrences (all)	1	3	
DIZZINESS			

subjects affected / exposed	1 / 9 (11.11%)	2 / 19 (10.53%)	
occurrences (all)	1	3	
DYSAESTHESIA			
subjects affected / exposed	3 / 9 (33.33%)	3 / 19 (15.79%)	
occurrences (all)	4	3	
DYSARTHRIA			
subjects affected / exposed	1 / 9 (11.11%)	0 / 19 (0.00%)	
occurrences (all)	1	0	
DYSGEUSIA			
subjects affected / exposed	2 / 9 (22.22%)	5 / 19 (26.32%)	
occurrences (all)	2	8	
HEADACHE			
subjects affected / exposed	2 / 9 (22.22%)	4 / 19 (21.05%)	
occurrences (all)	2	4	
HYPOAESTHESIA			
subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)	
occurrences (all)	0	1	
NEUROPATHY PERIPHERAL			
subjects affected / exposed	5 / 9 (55.56%)	4 / 19 (21.05%)	
occurrences (all)	11	7	
NEUROTOXICITY			
subjects affected / exposed	0 / 9 (0.00%)	2 / 19 (10.53%)	
occurrences (all)	0	4	
PARAESTHESIA			
subjects affected / exposed	1 / 9 (11.11%)	0 / 19 (0.00%)	
occurrences (all)	1	0	
TREMOR			
subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)	
occurrences (all)	0	1	
Blood and lymphatic system disorders			
ANAEMIA			
subjects affected / exposed	4 / 9 (44.44%)	5 / 19 (26.32%)	
occurrences (all)	8	9	
ANAEMIA MACROCYTIC			
subjects affected / exposed	1 / 9 (11.11%)	0 / 19 (0.00%)	
occurrences (all)	1	0	

HEPARIN-INDUCED THROMBOCYTOPENIA			
subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)	
occurrences (all)	0	1	
LEUKOCYTOSIS			
subjects affected / exposed	1 / 9 (11.11%)	0 / 19 (0.00%)	
occurrences (all)	1	0	
NEUTROPENIA			
subjects affected / exposed	1 / 9 (11.11%)	3 / 19 (15.79%)	
occurrences (all)	1	7	
THROMBOCYTOPENIA			
subjects affected / exposed	0 / 9 (0.00%)	3 / 19 (15.79%)	
occurrences (all)	0	7	
IRON DEFICIENCY ANAEMIA			
subjects affected / exposed	1 / 9 (11.11%)	2 / 19 (10.53%)	
occurrences (all)	1	2	
Ear and labyrinth disorders			
VERTIGO			
subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)	
occurrences (all)	0	1	
Eye disorders			
CATARACT			
subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)	
occurrences (all)	0	1	
VISION BLURRED			
subjects affected / exposed	1 / 9 (11.11%)	0 / 19 (0.00%)	
occurrences (all)	1	0	
DRY EYE			
subjects affected / exposed	1 / 9 (11.11%)	1 / 19 (5.26%)	
occurrences (all)	1	1	
LACRIMATION INCREASED			
subjects affected / exposed	1 / 9 (11.11%)	1 / 19 (5.26%)	
occurrences (all)	1	1	
PHOTOPHOBIA			
subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)	
occurrences (all)	0	1	
CONJUNCTIVAL HYPERAEMIA			

subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)	
occurrences (all)	0	1	
VITREOUS FLOATERS			
subjects affected / exposed	0 / 9 (0.00%)	2 / 19 (10.53%)	
occurrences (all)	0	2	
Gastrointestinal disorders			
HYPOAESTHESIA ORAL			
subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)	
occurrences (all)	0	2	
ABDOMINAL PAIN			
subjects affected / exposed	4 / 9 (44.44%)	3 / 19 (15.79%)	
occurrences (all)	4	6	
ABDOMINAL PAIN LOWER			
subjects affected / exposed	1 / 9 (11.11%)	0 / 19 (0.00%)	
occurrences (all)	1	0	
ABDOMINAL PAIN UPPER			
subjects affected / exposed	2 / 9 (22.22%)	3 / 19 (15.79%)	
occurrences (all)	3	3	
COLITIS			
subjects affected / exposed	1 / 9 (11.11%)	0 / 19 (0.00%)	
occurrences (all)	1	0	
CONSTIPATION			
subjects affected / exposed	3 / 9 (33.33%)	7 / 19 (36.84%)	
occurrences (all)	4	9	
DEFAECATION URGENCY			
subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)	
occurrences (all)	0	1	
DIARRHOEA			
subjects affected / exposed	4 / 9 (44.44%)	11 / 19 (57.89%)	
occurrences (all)	13	25	
DRY MOUTH			
subjects affected / exposed	0 / 9 (0.00%)	3 / 19 (15.79%)	
occurrences (all)	0	3	
DYSPEPSIA			
subjects affected / exposed	1 / 9 (11.11%)	1 / 19 (5.26%)	
occurrences (all)	1	1	

FAECES DISCOLOURED				
subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)		
occurrences (all)	0	1		
FAECES SOFT				
subjects affected / exposed	1 / 9 (11.11%)	0 / 19 (0.00%)		
occurrences (all)	1	0		
FLATULENCE				
subjects affected / exposed	2 / 9 (22.22%)	3 / 19 (15.79%)		
occurrences (all)	2	3		
GASTROOESOPHAGEAL REFLUX DISEASE				
subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)		
occurrences (all)	0	1		
HAEMORRHOIDAL HAEMORRHAGE				
subjects affected / exposed	1 / 9 (11.11%)	0 / 19 (0.00%)		
occurrences (all)	2	0		
HAEMORRHOIDS				
subjects affected / exposed	1 / 9 (11.11%)	1 / 19 (5.26%)		
occurrences (all)	1	1		
ABDOMINAL DISCOMFORT				
subjects affected / exposed	2 / 9 (22.22%)	0 / 19 (0.00%)		
occurrences (all)	3	0		
ILEUS				
subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)		
occurrences (all)	0	1		
LIP DRY				
subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)		
occurrences (all)	0	1		
NAUSEA				
subjects affected / exposed	7 / 9 (77.78%)	10 / 19 (52.63%)		
occurrences (all)	16	13		
ORAL DYSAESTHESIA				
subjects affected / exposed	1 / 9 (11.11%)	0 / 19 (0.00%)		
occurrences (all)	1	0		
PANCREATIC FAILURE				

subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)	
occurrences (all)	0	1	
PARAESTHESIA ORAL			
subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)	
occurrences (all)	0	1	
RECTAL HAEMORRHAGE			
subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)	
occurrences (all)	0	1	
STEATORRHOEA			
subjects affected / exposed	1 / 9 (11.11%)	0 / 19 (0.00%)	
occurrences (all)	1	0	
STOMATITIS			
subjects affected / exposed	1 / 9 (11.11%)	1 / 19 (5.26%)	
occurrences (all)	1	1	
VOMITING			
subjects affected / exposed	3 / 9 (33.33%)	8 / 19 (42.11%)	
occurrences (all)	4	13	
LARGE INTESTINAL OBSTRUCTION			
subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)	
occurrences (all)	0	1	
Hepatobiliary disorders			
JAUNDICE			
subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)	
occurrences (all)	0	1	
CHOLANGITIS			
subjects affected / exposed	1 / 9 (11.11%)	0 / 19 (0.00%)	
occurrences (all)	1	0	
HYPERTRANSAMINASAEMIA			
subjects affected / exposed	2 / 9 (22.22%)	0 / 19 (0.00%)	
occurrences (all)	2	0	
PORTAL VEIN THROMBOSIS			
subjects affected / exposed	0 / 9 (0.00%)	2 / 19 (10.53%)	
occurrences (all)	0	2	
Skin and subcutaneous tissue disorders			
ERYTHEMA			

subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)		
occurrences (all)	0	1		
DRY SKIN				
subjects affected / exposed	1 / 9 (11.11%)	1 / 19 (5.26%)		
occurrences (all)	1	1		
DERMATITIS ACNEIFORM				
subjects affected / exposed	1 / 9 (11.11%)	0 / 19 (0.00%)		
occurrences (all)	2	0		
DECUBITUS ULCER				
subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)		
occurrences (all)	0	1		
COLD SWEAT				
subjects affected / exposed	1 / 9 (11.11%)	0 / 19 (0.00%)		
occurrences (all)	1	0		
SKIN DISCOLOURATION				
subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)		
occurrences (all)	0	1		
SERPENTINE SUPRAVENOUS HYPERPIGMENTATION				
subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)		
occurrences (all)	0	1		
RASH PRURITIC				
subjects affected / exposed	1 / 9 (11.11%)	0 / 19 (0.00%)		
occurrences (all)	1	0		
RASH				
subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)		
occurrences (all)	0	1		
PRURITUS				
subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)		
occurrences (all)	0	1		
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME				
subjects affected / exposed	1 / 9 (11.11%)	0 / 19 (0.00%)		
occurrences (all)	1	0		
HYPERHIDROSIS				

subjects affected / exposed	1 / 9 (11.11%)	2 / 19 (10.53%)	
occurrences (all)	1	2	
SKIN ULCER			
subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)	
occurrences (all)	0	1	
SKIN HYPERPIGMENTATION			
subjects affected / exposed	1 / 9 (11.11%)	1 / 19 (5.26%)	
occurrences (all)	1	1	
NIGHT SWEATS			
subjects affected / exposed	0 / 9 (0.00%)	2 / 19 (10.53%)	
occurrences (all)	0	2	
Renal and urinary disorders			
STERILE PYURIA			
subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)	
occurrences (all)	0	1	
PROTEINURIA			
subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)	
occurrences (all)	0	1	
Musculoskeletal and connective tissue disorders			
FLANK PAIN			
subjects affected / exposed	1 / 9 (11.11%)	0 / 19 (0.00%)	
occurrences (all)	1	0	
BACK PAIN			
subjects affected / exposed	1 / 9 (11.11%)	5 / 19 (26.32%)	
occurrences (all)	2	7	
ARTHRALGIA			
subjects affected / exposed	1 / 9 (11.11%)	2 / 19 (10.53%)	
occurrences (all)	2	2	
GROIN PAIN			
subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)	
occurrences (all)	0	1	
MUSCLE SPASMS			
subjects affected / exposed	0 / 9 (0.00%)	2 / 19 (10.53%)	
occurrences (all)	0	2	
MUSCULAR WEAKNESS			

subjects affected / exposed	0 / 9 (0.00%)	2 / 19 (10.53%)	
occurrences (all)	0	3	
MUSCULOSKELETAL CHEST PAIN			
subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)	
occurrences (all)	0	1	
PAIN IN EXTREMITY			
subjects affected / exposed	1 / 9 (11.11%)	1 / 19 (5.26%)	
occurrences (all)	1	2	
PAIN IN JAW			
subjects affected / exposed	1 / 9 (11.11%)	0 / 19 (0.00%)	
occurrences (all)	1	0	
BONE PAIN			
subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)	
occurrences (all)	0	1	
Infections and infestations			
CLOSTRIDIUM DIFFICILE INFECTION			
subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)	
occurrences (all)	0	1	
COVID-19			
subjects affected / exposed	1 / 9 (11.11%)	0 / 19 (0.00%)	
occurrences (all)	1	0	
GENITAL CANDIDIASIS			
subjects affected / exposed	1 / 9 (11.11%)	0 / 19 (0.00%)	
occurrences (all)	1	0	
HERPES SIMPLEX REACTIVATION			
subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)	
occurrences (all)	0	1	
ORAL CANDIDIASIS			
subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)	
occurrences (all)	0	1	
OROPHARYNGEAL CANDIDIASIS			
subjects affected / exposed	1 / 9 (11.11%)	0 / 19 (0.00%)	
occurrences (all)	1	0	
PNEUMONIA			
subjects affected / exposed	1 / 9 (11.11%)	1 / 19 (5.26%)	
occurrences (all)	1	1	

RASH PUSTULAR			
subjects affected / exposed	1 / 9 (11.11%)	0 / 19 (0.00%)	
occurrences (all)	1	0	
SKIN CANDIDA			
subjects affected / exposed	1 / 9 (11.11%)	0 / 19 (0.00%)	
occurrences (all)	1	0	
URINARY TRACT INFECTION			
subjects affected / exposed	1 / 9 (11.11%)	2 / 19 (10.53%)	
occurrences (all)	1	2	
VAGINAL INFECTION			
subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)	
occurrences (all)	0	1	
VULVOVAGINAL MYCOTIC INFECTION			
subjects affected / exposed	0 / 9 (0.00%)	1 / 19 (5.26%)	
occurrences (all)	0	1	
CANDIDA INFECTION			
subjects affected / exposed	0 / 9 (0.00%)	2 / 19 (10.53%)	
occurrences (all)	0	2	
Metabolism and nutrition disorders			
DECREASED APPETITE			
subjects affected / exposed	5 / 9 (55.56%)	6 / 19 (31.58%)	
occurrences (all)	8	8	
DEHYDRATION			
subjects affected / exposed	0 / 9 (0.00%)	2 / 19 (10.53%)	
occurrences (all)	0	2	
DIABETES MELLITUS			
subjects affected / exposed	1 / 9 (11.11%)	0 / 19 (0.00%)	
occurrences (all)	1	0	
HYPERGLYCAEMIA			
subjects affected / exposed	1 / 9 (11.11%)	0 / 19 (0.00%)	
occurrences (all)	1	0	
HYPERKALAEMIA			
subjects affected / exposed	1 / 9 (11.11%)	0 / 19 (0.00%)	
occurrences (all)	1	0	
HYPOALBUMINAEMIA			

subjects affected / exposed	2 / 9 (22.22%)	1 / 19 (5.26%)	
occurrences (all)	2	1	
HYPOCALCAEMIA			
subjects affected / exposed	0 / 9 (0.00%)	2 / 19 (10.53%)	
occurrences (all)	0	2	
HYPOGLYCAEMIA			
subjects affected / exposed	2 / 9 (22.22%)	0 / 19 (0.00%)	
occurrences (all)	2	0	
HYPOKALAEMIA			
subjects affected / exposed	3 / 9 (33.33%)	5 / 19 (26.32%)	
occurrences (all)	4	8	
HYPOMAGNESAEMIA			
subjects affected / exposed	3 / 9 (33.33%)	4 / 19 (21.05%)	
occurrences (all)	3	7	
HYPOPHOSPHATAEMIA			
subjects affected / exposed	1 / 9 (11.11%)	1 / 19 (5.26%)	
occurrences (all)	1	1	
HYPONATRAEMIA			
subjects affected / exposed	1 / 9 (11.11%)	2 / 19 (10.53%)	
occurrences (all)	2	2	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
23 February 2021	Version 2.0, Global Amendment updated eligibility criteria, time requirements for prohibited medications, toxicity management, DLT criteria and statistical analyses.
25 May 2021	Version 3.0, Global Amendment updated DLT criteria.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? Yes

Date	Interruption	Restart date
10 July 2023	The sponsor closed the study for business reasons and not for safety reasons. At the time of notification to close, active subjects remained in Cohort 2 of the Phase 1b dose escalation, and enrollment in Phase 2 was not initiated. All subjects, regardless of reason for discontinuation of study treatment, underwent a final study visit and were followed for progression and survival.	-

Notes:

Limitations and caveats

None reported